Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From May 2019 to May 2024
TKT to Present at Wachovia Biotechnology Conference
CAMBRIDGE, Mass., Dec. 9 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) today announced that the company will present at Wachovia
Capital Markets' Ten for '05 Biotechnology Conference being held at the Ritz
Carlton, Central Park in New York on December 16, 2004. The conference will
feature ten companies expected to report pivotal clinical trial results in
2005. David D. Pendergast, Ph.D., Chief Operating Officer of TKT, will present
an overview of the company's AIM study (Assessment of I2S in MPS II) at 9:30
a.m. Eastern Standard Time. The AIM study is a pivotal trial evaluating
iduronate-2-sulfatase (I2S), TKT's investigational enzyme replacement therapy
being development for the treatment of Hunter syndrome. TKT expects top-line
results from the AIM study in June 2005, and, if positive, the company expects
to submit applications for marketing approval in both the United States and
Europe in the second half of 2005.
A live audio webcast of this presentation will be available at
http://www.tktx.com/ on TKT's Investor Information website under the Events
category. A replay will be available for approximately 30 days after the
webcast.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
For More Information Contact:
Daniella M. Lutz
Corporate Communications Manager
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html